<DOC>
	<DOCNO>NCT01195181</DOCNO>
	<brief_summary>Hepatitis C virus ( HCV ) infection provokes thousand death every year world , major cause progressive liver disease , primary hepatic cancer liver transplantation . Today , `` curative '' therapy available , eradicate viral infection determine regression liver fibrosis , also cirrhotic subject . The current standard-of-care HCV chronic infection combination therapy peginterferon ( P-IFN ) ribavirin ( RBV ) . However , treatment expensive determines several side effect , reduce drug tolerance hence , patient adherence therapy . There two type available P-IFN market : P-IFN alfa-2a ( Pegasys速 , F.Hoffmann-La Roche ) administer flat-dose 180 mcg/week P-IFN alfa-2b ( PegIntron速 , Schering-Plough ) give weight-based dose 50 150 mcg/week . Since single amino acid differentiate type IFN , administration strategy depend pegilation molecule 40 12kDa , respectively , account difference pharmacokinetic pharmacodynamic drug-profile influence probably also bioactivity . No comparative data available benefit cost license Peg-IFN plus RBV treatment HCV infection real clinical practice , even , benefit favourable cost-efficacy antiviral therapy well establish large consensus . Recently , first randomize control mega-trial compare antiviral therapeutic efficacy na誰ve patient HCV-genotype 1 infection different regimens P-IFN alfa-2b ( low standard-dose ) P-IFN alfa-2a plus RBV , publish , confirm similar efficacy , around 40 % , obtain three schedule evaluate . In Italy , regional program Surveillance Control HCV Infection , set Regional Health Councillorship , lead development clinical epidemiological observatory , constitute network liver tertiary centre ( Hepatological Cooperative Network Veneto , HepCoVe ) . This collaborative group connect on-line common database , since 2003 , prospectively collect data cohort 3000 patient chronic HCV infection , among , 506 na誰ve subject consecutively underwent combination therapy P-IFN alfa-2a alfa-2b plus RBV . The aim study rationalize improve social regional health program antiviral treatment chronic hepatitis C assess different schedule utilization P-IFN plus RBV well respective therapeutic effectiveness , safety cost real clinical practice ( Project A ) .</brief_summary>
	<brief_title>Different PEG-interferon Ribavirin Schedules Chronic Hepatitis C Real Clinical Practice .</brief_title>
	<detailed_description>( Project B ) To evaluate viral kinetic decay antiviral combination therapy P-IFN alfa-2a 2b type plus ribavirin .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Naive adult subject active HCV infection ( HCVRNA positive ) histological/biochemical sign chronic hepatitis compensate cirrhosis willingness treatment autoimmune disorder severe depression psychiatric disease previous decompensation cirrhosis gastroesophageal bleed hepatocellular carcinoma major disease life expectancy le 5 year pregnancy nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>peginterferon alfa 2a 2b type</keyword>
	<keyword>ribavirin</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>antiviral therapy cost/efficacy</keyword>
	<keyword>viral kinetics</keyword>
</DOC>